Thyroid News and Research

RSS

Harley Street Fertility Clinic encourages couples to have more sex to increase chances of conception

Today, one of the UK’s leading fertility experts warns that couples with busy lives are not engaging in enough sexual intercourse and this is therefore impacting the nations fertility.

21 Dec 2015

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015

Multiple small doses of targeted radiation therapy more effective at destroying pituitary gland tumors

A recent patient study at Houston Methodist Hospital proved that multiple small doses of highly focused radiation therapy is safer and more effective than a single larger dose of radiation at destroying pituitary gland tumors.

18 Dec 2015

Environmental exposures and behaviors contribute to the majority of cancers, study shows

Researchers have found that extrinsic factors such as environmental exposures and behaviors contribute heavily to the development of the vast majority of cancers.

17 Dec 2015

ACS, Alliance begin work on second volume of manual for cancer surgery

The American College of Surgeons and the Alliance for Clinical Trials in Oncology announced that they have begun work on the second volume of a comprehensive, evidence-based examination of cancer surgery techniques and recommendations.

17 Dec 2015

Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

Array BioPharma today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment.

16 Dec 2015

New biobank initiative may help unlock some of the mysteries linked to Down syndrome

Nationwide Children's Hospital and research advocacy group DownSyndrome Achieves have joined forces to create the first biobank in the country dedicated to collecting and managing blood samples from people with Down syndrome.

12 Dec 2015

New research sheds light on outcomes for patients with thyroid cancer

Thyroid cancer survivors report poor quality of life after diagnosis and treatment compared with other patients who are diagnosed with more lethal cancers, according to new research from the University of Chicago Medicine.

12 Dec 2015

Advanced thyroid cancer rates above national average in several parts of California

A team of UCLA researchers found that there are several parts of California where, in a high percentage of people with thyroid cancer, the disease is already at an advanced stage by the time it is diagnosed.

11 Dec 2015

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Progesterone supplements fail to improve birth rate among women with a history of miscarriage

A new study has shown that taking progesterone supplements during the first trimester of pregnancy does not improve the chances of maintaining pregnancy among women who have a history of unexplained recurrent miscarriage.

26 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

Patients with kidney failure at increased risk of developing different types of cancer

For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology, suggest the need for persistent cancer screening and prevention in these patients.

13 Nov 2015

Study highlights possible inaccuracies in thyroid cancer detection tests

Protein biomarkers are used to test for cancer before and after surgeries to remove tumors. To test thyroid malignancy, many biomarkers are tested separately to confirm cancer. However, new research from Michigan Technological University shows that the detection tests that measure two major biomarkers to diagnose thyroid cancer may be inaccurate.

13 Nov 2015

Eight myths and truths about Alzheimer's disease

Although Alzheimer's disease (AD) impacts more than five million Americans and 15 million caregivers year-round, the nation is especially focused on the disease this month as it observes "National Alzheimer's Disease and Awareness Month."

11 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States.

6 Nov 2015

Gastric reduction surgery can significantly increase patient's risk of developing allergy

Amongst other things, operations to reduce the size of the stomach can significantly increase the patient's risk of developing an allergy. This is the conclusion of a study conducted by the Medical University of Vienna.

4 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015